Présentation de l'entreprise
Alexandria Real Estate Equities, Inc. operates as an S&P 500 company specializing in the ownership and management of life science real estate properties, having pioneered this specific niche since its founding in 1994. The enterprise functions within the Real Estate sector and the REIT - Office industry, positioning it as a preeminent and longest-tenured owner in its field while delivering a mission-driven impact on the global life science ecosystem. The company currently commands a market capitalization of $7.77B, generates annual revenue of $3.02B, and employs a workforce of 514 individuals across its portfolio. These valuation and revenue figures underscore Alexandria's status as a major player in the specialized real estate market, reflecting a significant asset base dedicated to supporting biotechnology and pharmaceutical research.
Santé financière
The company reported a trailing twelve-month revenue of $3.02B, yet simultaneously posted a net income of $-1,437,986,944, revealing a substantial divergence between top-line activity and bottom-line profitability that points to significant non-operating expenses or one-time charges affecting the cost structure. Despite the negative net income, the firm maintains robust operational efficiency with an EBITDA of $1.94B, which translates into a Free Cash Flow of $1.35B, indicating strong financial flexibility to service debt obligations or fund capital expenditures independent of net income fluctuations. The margin profile is complex, featuring a Gross Margin of 69.4% and an Operating Margin of 22.7%, which suggest healthy pricing power and operational control, contrasted sharply by a Profit Margin of -47.4% that highlights the severe impact of interest or other non-operating costs on the final profit. The balance sheet shows a Cash position of $549.06M against a total Debt load of $12.76B, resulting in a Debt to Equity ratio of 66.61, which characterizes the entity as highly leveraged rather than conservative. Liquidity in the short term appears manageable with a Current Ratio of 1.62, suggesting the company holds sufficient current assets to cover its current liabilities without immediate distress. However, the Return on Equity stands at -5.9% and the Return on Assets is 1.1%, metrics that collectively reveal management's current inability to generate net returns on shareholder capital or total assets due to the net income deficit.
Évaluation de la valorisation
Valuation metrics present a stark picture, with a Trailing P/E (TTM) listed as N/A due to the negative earnings, while the Forward P/E is reported at -560.50, implying that the market is pricing in a significant turnaround in expected earnings trajectory or that the current multiple is not applicable under traditional models. The Price to Book ratio is 0.49, indicating that the market values the company at significantly less than its book value, which may reflect investor caution regarding the negative net income or sector-specific headwinds. Alternative valuation multiples provide further context, with a Price to Sales ratio of 2.58 and an EV/EBITDA of 12.20, suggesting the market is willing to pay a premium relative to sales and earnings before interest, taxes, depreciation, and amortization despite the earnings shortfall. Price action over the last year has been volatile, with a 52-Week High of $88.24 and a 52-Week Low of $41.44, placing the current trading environment within a wide range that reflects the asset's sensitivity to interest rate environments and life science sector dynamics. The stock exhibits a Beta of 1.34, meaning its price volatility is approximately 34% higher than the broader market, exposing investors to increased risk during periods of market turbulence.
Growth & Income
Revenue growth over the last year has contracted by -5.2%, while Earnings Growth is listed as N/A due to the negative net income, indicating that the company is currently in a period of financial restructuring or heavy capital investment rather than organic earnings expansion. The company maintains a Dividend Yield of 9.1% with a Payout Ratio of 689.5%, a combination that suggests the dividend is being funded from cash flows rather than net income, raising questions about long-term sustainability given the earnings deficit. Since the net income is negative, the company technically cannot sustain a payout ratio based on earnings alone, relying instead on its Free Cash Flow of $1.35B to fund the distribution, which is an aggressive strategy that could be vulnerable if cash flow generation deteriorates. Overall, Alexandria Real Estate Equities, Inc. presents a growth and income profile characterized by high current yield and significant leverage, with recent revenue contraction and negative profitability offset by strong operational cash generation.